Finasteride Does Not Reduce Skin Oiliness or Improve Skin Clarity
Finasteride is NOT the medication you're asking about - you appear to be confusing finasteride (a 5α-reductase inhibitor used for male pattern baldness and prostate enlargement) with a combined oral contraceptive containing cyproterone acetate/ethinyl estradiol. Finasteride is actually contraindicated in women of reproductive potential due to risk of genital abnormalities in male fetuses 1.
What You're Actually Asking About
Based on your expanded question mentioning "cyproterone acetate 2 mg/ethinyl-estradiol 0.035 mg," you're asking about a combined oral contraceptive (COC), not finasteride.
Does Cyproterone Acetate/Ethinyl Estradiol Reduce Oiliness and Clear Skin?
Yes, cyproterone acetate 2 mg combined with ethinyl estradiol 35 μg (CPA/EE) effectively reduces skin oiliness (seborrhea) and clears acne through its antiandrogenic properties [@2-5@, 2].
Mechanism of Action
CPA/EE works through multiple antiandrogenic pathways 2, 3:
- Inhibits androgen receptors directly (cyproterone acetate's primary action)
- Suppresses ovarian androgen production via gonadotropin suppression
- Increases sex hormone-binding globulin (SHBG), binding free testosterone and making it unavailable
- Reduces 5α-reductase activity, decreasing conversion of testosterone to DHT
- Directly reduces sebaceous gland activity, leading to less oily skin
Clinical Evidence for Skin Improvement
Acne Reduction
A large multicenter study of 890 women with facial acne showed 4:
- 82.8% achieved "good" or "very good" response (>50% lesion reduction) after 6 cycles
- Reductions in all lesion types: comedones (75.6-80%), papules (88.4%), pustules (85.1%)
- 64.3% showed lower acne grade by study end
- Only 4.9% experienced worsening
Seborrhea (Oiliness) Reduction
Multiple studies confirm CPA/EE significantly reduces sebum production 5, 6:
- Direct measurement showed marked reduction in sebum output
- Clinical improvement in seborrhea observed alongside acne improvement
- Effects maintained throughout treatment duration
Comparative Effectiveness
When compared to other COCs 5, 7:
- CPA/EE performs as well or better than other antiandrogenic COCs for acne and seborrhea
- Superior to levonorgestrel-containing COCs 7
- Comparable efficacy to drospirenone-containing COCs 3
Important Clinical Considerations
Time to Effect
- Minimum 6-month trial recommended before assessing full response 8, 3
- Improvements typically begin within 3 months but continue to increase
- Sebum reduction may be noticed earlier than complete acne clearance
Safety Profile
CPA/EE carries standard COC risks [@3-5@]:
Venous Thromboembolism (VTE):
- Baseline risk: 1-5 per 10,000 woman-years (non-users)
- CPA/EE users: 3-9 per 10,000 woman-years
- 50-80% higher VTE risk than levonorgestrel-COCs but still low absolute risk 2
Contraindications include:
- Age ≥35 years with smoking
- History of VTE, stroke, or MI
- Uncontrolled hypertension
- Migraine with aura (if ≥35 years)
- Current or recent breast cancer
- Pregnancy or breastfeeding <6 weeks postpartum 2
Who Benefits Most
Best candidates for CPA/EE 8, 6, 9:
- Women with moderate-to-severe acne related to androgen sensitivity
- Those with accompanying seborrhea (oily skin)
- Women with polycystic ovary syndrome (PCOS)
- Those experiencing acne flares around menses
- Women who also desire contraception (FDA requirement for acne indication)
Common Pitfall to Avoid
Do not confuse finasteride with CPA/EE. Finasteride is:
- A 5α-reductase inhibitor used in men for hair loss and prostate issues 1
- Absolutely contraindicated in women who may become pregnant 1
- Has limited evidence in women (only studied for hirsutism at 5-7.5 mg doses) 3, 10
- Does NOT have the same comprehensive antiandrogenic effects as CPA/EE
The correct medication for reducing skin oiliness and clearing acne in women is cyproterone acetate 2 mg/ethinyl estradiol 35 μg, not finasteride.